- Home
- SDST vs BTAI Comparison
SDST vs BTAI Comparison
Compare SDST & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDST | BTAI |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SDST | BTAI |
|---|---|---|
| Price | $3.49 | $2.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $17.00 | ★ $32.80 |
| AVG Volume (30 Days) | 113.6K | ★ 661.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.43 | $1.17 |
| 52 Week High | $70.25 | $9.26 |
Technical Indicators
Market Signals| Indicator | SDST | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 51.76 |
| Support Level | $3.06 | $1.82 |
| Resistance Level | $3.74 | $2.33 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 53.57 | 62.87 |
Price Performance
Historical ComparisonAbout SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.